argenx Announces 2021 Corporate Priorities and Highlights Recent Achievements Across Immunology Pipeline
argenx Announces 2021 Corporate Priorities and Highlights Recent Achievements Across Immunology Pipeline argenx Announces 2021 Corporate Priorities and Highlights Recent Achievements Across Immunology Pipeline Submitted Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) for efgartigimod in generalized myasthenia gravis (gMG) Initiated 50-patient gMG bridging study of subcutaneous (SC) efgartigimod based on FDA feedback Enrolled first 30 patients, necessary for go/no-go decision, in ADHERE trial of SC efgartigimod for chronic inflammatory demyelinating polyneuropath...
Source: globalbankingandfinance.com